Evidence map›Paper›PMID 35188222›Full record

ArticleJournal of the American Geriatrics Society2022

Stakeholders' views on priorities essential for establishing a supportive environment for clinical trials in nursing homes.

Christopher Delude, Ivan H Abi-Elias, Charlene C Quinn, Alyce S Adams, Jay S Magaziner, Kouta Ito, Paavani Jain, Jerry H Gurwitz, Kathleen M Mazor

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Geriatrics Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Christopher DeludeMeyers Health Care Institute, Worcester, Massachusetts, USA.
Ivan H Abi-EliasMeyers Health Care Institute, Worcester, Massachusetts, USA.ORCID 0000-0002-9306-7487
Charlene C QuinnUniversity of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-6066-2984
Alyce S AdamsStanford University School of Medicine, Stanford, California, USA.
Jay S MagazinerUniversity of Maryland School of Medicine, Baltimore, Maryland, USA.
Kouta ItoMeyers Health Care Institute, Worcester, Massachusetts, USA.
Paavani JainUniversity of Maryland School of Medicine, Baltimore, Maryland, USA.
Jerry H GurwitzMeyers Health Care Institute, Worcester, Massachusetts, USA.
Kathleen M MazorMeyers Health Care Institute, Worcester, Massachusetts, USA.
University of Maryland, Baltimore · USUniversity of Massachusetts Chan Medical School · USFamily Health Center of Worcester · USStanford University · US

Funding

University of Maryland Claude D. Pepper Older Americans Independence Center (UM-OAIC)P30AG028747 · NIA · UNIVERSITY OF MARYLAND BALTIMORE · PI Stephen L. Seliger · 2006 to 2026
$28.9M
Translational Research Core - Health Engagement & Action Translational (HEAT)P30DK092924 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI Alyce Sophia Adams, HILARY Kessler SELIGMAN · 2011 to 2026
$9.2M
Preparing For What Is Next With Aducanumab In Real World SettingsR33AG057806 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Christopher Barrett Bowling, Ana Roman Quinones · 2018 to 2026
$9.0M
NIA NIH HHS 3R33 AG057806-03S1NIA NIH HHS 5R33 AG057806-04NIA NIH HHS P30 AG028747NIA NIH HHS R33 AG057806NIDDK NIH HHS P30 DK092924
6 · The paper itself

Abstract

backgroundThe U.S. clinical research enterprise in nursing homes was unprepared to mount clinical trials in nursing homes to address urgent questions relevant to prevention and treatment during the COVID-19 pandemic. We identify priorities essential for establishing a supportive environment for future clinical trials in nursing homes.

methodsTwo cross-sectional online questionnaires were administered between January and February 2021. One was administered to nursing home providers, researchers, and policymakers; respondents rated the importance of attributes of researchers, facilities, leaders and staff for conducting clinical trials in nursing homes. Because importance may depend on trial type, respondents rated each attribute for efficacy trials (testing an intervention in ideal circumstances) and effectiveness trials (testing an intervention in "real world" circumstances). We calculated the attribute rating means and standard deviations, and used content analysis to characterize open-ended responses. The second questionnaire for resident family members and advocates included open-ended questions about nursing home research, and factors influencing willingness to participate.

resultsThe attributes rated as most essential for conducting efficacy and effectiveness trials in nursing homes are research team attributes, that is, that researchers recognize regulatory constraints; understand and adapt to nursing home workflow; and work collaboratively with nursing home leaders to identify priorities. Resident and facility diversity emerged as essential for effectiveness trials; important dimensions included resident race, ethnicity and income, as well as nursing home urban/rural location, quality ratings, geography, staffing ratios, size, and profit status. Caregivers and resident advocates stressed the importance of communication among participants, researchers, and nursing home leadership and staff at all stages of a trial.

conclusionDeveloping a robust U.S. clinical research enterprise capable of efficiently mounting future clinical trials in nursing homes will require a reimagining of the relationships that exist between researchers, facilities, nursing home leaders, and residents, with a research infrastructure specifically focused on supporting and fostering these connections.

Indexed as

COVID-19PandemicsCross-Sectional StudiesHumansNursing HomesSurveys and Questionnairesclinical trialsCOVID-19nursing homesresources

Identifiers

PMID35188222
PMCPMC8986625
OpenAlexW4213274058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.